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Summary
Fatty acid amide hydrolase (FAAH) regulates a large
class of signaling lipids, including the endocannabi-
noid anandamide. Carbamate inhibitors of FAAH dis-
play analgesic and anxiolytic properties in rodents.
However, the mechanism by which carbamates inhibit
FAAH remains obscure. Here, we provide biochemical
evidence that carbamates covalently modify the active
site of FAAH by adopting an orientation opposite of
that originally predicted from modeling. Based on
these results, a series of carbamates was designed that
display enhanced potency. One agent was converted
into a ‘‘click chemistry’’ probe to comprehensively
evaluate the proteome reactivity of FAAH-directed car-
bamates in vivo. These inhibitors were selective for
FAAH in the nervous system, but they reacted with sev-
eral enzymes in peripheral tissues. The experimental
strategy described herein can be used to create in vivo
probes for any enzyme susceptible to covalent
inhibition.
Introduction
A wide range of lipids serve as endogenous signaling
molecules in both the nervous system and periphery, in-
cluding prostaglandins [1], lysophospholipids [2], and
fatty acids and their derivatives [3, 4]. One class of lipid
transmitters, the fatty acid amides [3, 4], has been
shown to modulate a number of physiological and be-
havioral processes, such as pain [5], feeding [6], and
sleep [7]. Representative fatty acid amides (FAAs) in-
clude the endogenous cannabinoid N-arachidonoyl eth-
anolamine (anandamide) [8], the anti-inflammatory lipid
N-palmitoyl ethanolamine (PEA) [9], and the sleep-in-
ducing substance 9(Z)-octadecenamide (oleamide) [7].
In contrast to aqueous-soluble chemical transmitters,
which can be sequestered within membrane compart-
ments for regulated release and uptake, lipids are free
to diffuse across cell bilayers, and, therefore, their sig-
naling capacity is primarily controlled by a dynamic bal-
ance between enzymatic biosynthesis and degradation.
In the nervous system, FAAs appear to be produced
from phospholipid precursors by a calcium-stimulated
two-step enzymatic pathway [10, 11]. The inactivation
of these lipids is predominantly mediated by enzymatic
hydrolysis, a process in which the integral membrane
protein fatty acid amide hydrolase (FAAH) plays a pri-
mary role [12].
*Correspondence: cravatt@scripps.eduFAAH2/2mice possess highly elevated levels of FAAs
throughout the central nervous system (CNS) and some
peripheral tissues [5, 13], a metabolic phenotype that
correlates with a cannabinoid receptor 1 (CB1)-depen-
dent reduction in pain sensation in these animals [14].
FAAH2/2 mice also exhibit reduced inflammation in
multiple peripheral models [13, 15], although this phe-
notype may be mediated, at least in part, by noncanna-
binoid FAAs [13]. Other than these specific alterations,
FAAH2/2 animals appear normal [5], suggesting that
this enzyme could represent an attractive therapeutic
target for pain, inflammation, and possibly other neural
disorders [16, 17]. Consistent with this premise, multiple
classes of FAAH inhibitors have been generated and
have been shown to produce CB1-dependent analgesic
[18, 19] and anxiolytic [20] effects in rodents.
FAAH is a member of an unusual class of serine hydro-
lases termed the amidase signature family, and it utilizes
a serine-serine-lysine catalytic triad [21, 22]. Despite its
atypical catalytic mechanism, FAAH is susceptible to
inhibition by most classical serine hydrolase-directed
inhibitors, including fluorophosphonates (FPs) [23], tri-
fluoromethyl ketones [24, 25], a-keto heterocycles [26],
and carbamates [20]. This fourth class of FAAH inhibitors
is particularly efficacious in vivo, possibly due to its pro-
posed irreversible mechanism of action, analogous to
the inactivation of acetylcholinesterase by commercial
carbamate drugs (e.g., pyridostigmine, rivastigmine)
for the treatment of Alzheimer’s disease [27]. The lead
carbamateFAAH inhibitorsURB532and URB597 (Table 1)
have been modeled into the FAAH active site, with initial
results suggesting that their biphenyl substituents mimic
the arachidonoyl chain of the FAAH substrate ananda-
mide [28]. However, no experimental data on the mech-
anism of carbamate inhibition of FAAH have yet been
reported. Here, we provide direct evidence that car-
bamates inactivate FAAH through a mechanism that
involves covalent carbamylation of the enzyme’s serine
nucleophile S241. Interestingly, these results suggest
that URB532 and URB597 bind to the FAAH active site
in an orientation opposite of that predicted from original
modeling studies. Based on these experimental data, we
designed: (1) a set of FAAH inhibitors with improved po-
tency, and (2) an active site-directed ‘‘click’’ chemistry
(CC) probe for functional analysis of FAAH activity and
inhibition in vivo. The CC probe was used to profile the
target selectivity of FAAH-directed carbamates in vivo,
providing a global view of proteomic ‘‘hot spots’’ for
off-target activity of these inhibitors.
Results
Characterization of the Mechanism of FAAH
Inhibition by Carbamates
Several carbamate inhibitors of FAAH have been de-
scribed in both the scientific [20] and patent [29] litera-
ture. The provocative behavioral effects of these
agents, including reductions in pain sensation [19, 29]
and anxiety [20], have provided support for FAAH as a
potential therapeutic target. Nonetheless, the mechanism
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Name Structure
Radioactive Substrate
IC50 (nM)
ABPP
IC50 (nM)
URB597 48 (41–57) 45 (31–65)
URB532 350 (215–570) 410 (260–660)
JP23 58 (32–110) 17 (13–23)
JP87 190 (95–400) 400 (290–540)
JP83 14 (10–18) 1.6 (1.2–2.2)
JP104 7.3 (5.6–9.6) 1.6 (1.2–2.1)
IC50 values (nM [95% confidence limits]) for FAAH carbamate inhibitors determined with purified recombinant enzyme by using a radiolabeled
substrate (14C-oleamide) assay [45] or with unsolubilized mouse brain membranes by competitive ABPP [39].by which carbamates inhibit FAAH remains obscure,
thus complicating efforts to rationally design second-
generation agents with superior potency and selectivity.
Carbamates typically inhibit serine hydrolases by an ir-
reversible (or slowly reversible) mechanism involving
carbamylation of the serine nucleophile [30]. Initial mod-
eling studies with the carbamates URB597 and URB532
suggested that their O-biaryl substituents reside in the
acyl chain binding (ACB) channel of FAAH, serving as a
more rigid structural mimetic of the arachidonoyl chain
of the FAAH substrate anandamide [28] (Figure 1A).
However, this orientation of binding would place the
N-alkyl substituents of carbamates in the cytoplasmic
access (CA) channel of FAAH in positions more suitable
for serving as leaving groups (akin to the ethanolamine
of anandamide), possibly resulting in carbonylation of
the enzyme’s nucleophile (Figure 2A). More recent
chemical reactivity studies have raised questions about
this model, as the extent of electrospray ionization-
induced cleavage of the C(O)-O bond in a series of FAAHcarbamate inhibitors was found to correlate with their
potency of inhibition [31], suggesting that O-aryl esters
may serve as leaving groups in FAAH-carbamate reac-
tions (carbamylation, Figure 2A). Finally, both of the
aforementioned models assume that carbamates inhibit
FAAH through a covalent mechanism of action, a prem-
ise that has not yet been directly tested.
To examine the mechanism of carbamate inhibition of
FAAH, purified recombinant enzyme was treated with
URB532 or URB597 for 1 hr, after which the protein
samples were subjected to tryptic digestion and
MALDI-TOF mass spectrometry (MS) analysis. In each
case, a new mass signal was observed for the inhibi-
tor-treated sample compared to untreated FAAH con-
trols that corresponded to the mass of the FAAH
tryptic peptide amino acids (AA) 217–243, which contain
the FAAH nucleophile S241 [32], modified by the C(O)-
N-alkyl substituent of the inhibitor (Figures 2B–2D). No
evidence of C(O)-O aryl modification of FAAH was de-
tected in either the URB532 or URB597 reaction. Liquid
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O-Biaryl Carbamate Inhibitors of FAAH
(A and B) The carbamate inhibitor URB597
was modeled into the FAAH active site in
two different orientations. In (A), the O-biaryl
group of URB597 is located in the acyl chain
binding (ACB) channel of FAAH and mimics
the location of the arachidonyl chain of FAAH
substrates/inhibitors [21]. In (B), the O-biaryl
group of URB597 is located in the cytoplas-
mic access (CA) channel of FAAH, positioning
the phenolic oxygen near the S217-K142 res-
idues of the catalytic triad (S241-S217-K142)
responsible for leaving group protonation.
Blue, basic; red, acidic; green, hydrophobic
(see [21] for more details on FAAH crystal
structure).chromatography-tandem electrospray MS (LC-MS)
analysis assigned the specific site of carbamylation to
S241 with high confidence (Xcorr = 6.04; DCN = 0.54).
These MS results indicated that URB532 and URB597
inhibit FAAH by carbamylation of the enzyme’s serine
nucleophile. As a corollary, the O-biaryl substituentsof these agents would be expected to reside in the CA
(rather than the ACB) channel of the FAAH active site,
where they would be susceptible to enzyme-catalyzed
protonation to enhance their function as leaving groups
[21, 33] (Figure 1B). To further test this prediction, we
synthesized a series of URB597 derivatives in whichFigure 2. Evidence that URB532 and URB597 Covalently Inhibit FAAH by Carbamylation of the Enzyme’s S241 Nucleophile
(A) Two possible modes for covalent labeling of FAAH by URB597. In the left scheme, the O-biaryl group of URB597 serves a leaving group,
resulting in carbamylation of the enzyme. In the right scheme, the N-cyclohexyl group of URB597 serves a leaving group, resulting in carbon-
ylation of the enzyme.
(B–D) The MS data shown support the left scheme. (B) MALDI-MS mapping of a tryptic digest of purified recombinant FAAH, highlighting the
tryptic peptide that contains the FAAH nucleophile S241 (AA213-243). (C and D) MALDI-MS mapping of a tryptic digest of FAAH pretreated
with (C) URB597 and (D) URB532, highlighting new tryptic peptides with masses that correspond to the AA213-243 peptide modified by
one molecule of C(O)NH-cyclohexane and C(O)NH-butane, respectively. Asterisked peptides correspond to other FAAH tryptic peptides.
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(A) General method for characterizing the proteome reactivity of JP104 in vivo. Mice are administered JP104 at escalating doses (e.g., 0.25–10
mg/kg, i.p.). After 1 hr, the animals are sacrificed, and their tissues are removed, homogenized, and reacted under CC conditions with an azide-
modified rhodamine reporter tag (RhN3). Labeled proteins are visualized by in-gel fluorescence scanning.
(B and C) Membrane protein reactivity profiles of JP104 in various mouse tissues. A single 65 kDa JP104 target was identified in brain (RhN3
lanes). (C) This protein was confirmed as FAAH based on its absence in FAAH2/2 brains (upper panel). The selective labeling of FAAH by JP104
in brain tissue was further supported by competitive ABPP experiments with the serine hydrolase-directed probe FP-rhodamine (FP-Rh),
which showed that none of the other brain serine hydrolases reacted with JP104 (FP-Rh lanes). (B) Additional targets of JP104 were identified
in liver and kidney (right panels, RhN3 lanes). (C) These proteins represented neither FAAH nor FAAH isoforms, as their labeling persisted in
FAAH2/2 tissues (middle and lower panels). Similar profiles were observed in soluble fractions of mouse kidney and liver (see Figure S2). Fluo-
rescence images are shown in grayscale.the N-cyclohexyl substituent was replaced with various
N-alkyl groups that mimicked the structures of acyl
chains of known FAAH substrates/inhibitors. These car-
bamates, which included N-oleyl (JP23) and N-(6-phe-
nyl)hexyl (JP83) analogs, were found to inhibit FAAH
with equal or greater potency than URB597 (Table 1).
These data indicate that the URB597 O-biaryl substitu-
ent can be accommodated in the CA channel of the
FAAH active site. Indeed, it appears that this group dis-
plays positive binding interactions with the CA channel,
as its replacement with a phenyl moiety (JP87) signifi-
cantly reduced inhibitor potency (Table 1).
Generation of a Click Chemistry Probe to Evaluate
the Proteome-Wide Reactivity of FAAH-Directed
Carbamates In Vivo
Covalent inhibitors, such as carbamates, are generally
regarded with skepticism as potential drugs due to their
inherent reactivity [34], which is perceived to compro-
mise target selectivity in vivo. Nonetheless, this asser-
tion often goes untested, as general methods todetermine the in vivo target selectivity of covalent inhib-
itors are lacking. The discovery that URB597 inhibited
FAAH via covalent carbamylation of the enzyme’s active
site inspired us to synthesize an N-alkynyl derivative of
this agent, JP104, which we hypothesized could be
used to directly identify the targets of FAAH-directed
carbamates in vivo. In this approach, tissues from ani-
mals treated with JP104 are reacted with a complemen-
tary azide-modified reporter tag (e.g., azido-rhodamine
[RhN3], azido-biotin [35, 36]) under CC conditions to af-
ford the corresponding triazole products (Figure 3A).
Initial in vitro experiments revealed that JP104 was a po-
tent FAAH inhibitor in vitro (Table 1) and selectively la-
beled this enzyme in brain membrane extracts (Figure
S1A; see the Supplemental Data available with this arti-
cle online). To further confirm the specificity of JP104 for
FAAH, we treated the JP104-labeled brain proteome
with a rhodamine-tagged fluorophosphonate (FP-Rh),
which serves as a general activity-based protein profil-
ing (ABPP) probe for the serine hydrolase superfamily
[37–39]. JP104 completely blocked FP-Rh labeling of
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other brain serine hydrolases at concentrations up to 10
mM (Figure S1B).
We next tested whether click chemistry (CC) methods
could be used to identify the targets of JP104 in vivo.
Mice were treated with JP104 (10 mg/kg, intraperitoneal
[i.p.]) for 1 hr, after which they were sacrificed and their
tissues removed for CC analysis. Consistent with in vitro
studies, FAAH was the primary in vivo target of JP104
observed in brain tissue (Figure 3B, left panel). In con-
trast, several additional targets of JP104, including mul-
tiple membrane-associated liver and kidney proteins,
were detected in peripheral tissues (Figure 3B, right
panels). These JP104-labeled proteins were also ob-
served in in vivo-labeled, soluble proteomes from kid-
ney and liver (Figure S2), as well as in FAAH2/2
tissues (Figure 3C), indicating that they do not represent
FAAH or potential FAAH isoforms. Dose-response pro-
files identified a concentration range for JP104 (0.25–
1.0 mg/kg) over which significant FAAH inhibition could
be achieved without extensive modification of addi-
tional targets (Figure 4). For example, at 1 mg/kg JP104,
FAAH labeling was w80% of maximum in the brain,
whereas none of the liver and kidney targets were mod-
ified to greater than 20%. The nearly complete inactiva-
tion of brain FAAH in vivo by 1 mg/kg JP104 was
confirmed by competitive ABPP studies with FP-Rh
(Figure 3B, left panel). In contrast, JP104 did not signif-
icantly reduce the intensity of FP-Rh signals in liver and
kidney proteomes (Figure 3B, right panels), which likely
reflects the presence of several comigrating serine hy-
drolase activities in the 60–65 kDa range in these tissues
(only a subset of which are modified by JP104). These
results indicate that carbamate-based inhibitors can
be designed that selectively target FAAH in vivo, albeit
over a somewhat limited concentration range.
Identification and Characterization of In Vivo
Targets of JP104
The molecular characterization of off-target sites of re-
activity for FAAH-directed carbamates would greatly
assist medicinal chemistry efforts aimed at improving
Figure 4. Dose Dependence of Protein Labeling by JP104 In Vivo
At 1 mg/kg JP104 (i.p.), the labeling of FAAH was approximately
80% of maximum, while none of the off-target sites were labeled
at greater than 20% of maximum. Data represent the average of
three trials per dose of JP104.the selectivity of these agents. With this goal in mind,
we reacted liver cytoplasmic proteomes from JP104-
treated mice (10 mg/kg, i.p.) with an azide-modified bi-
otin tag under CC conditions. Biotinylated proteins were
then enriched by avidin chromatography, separated by
SDS-PAGE, and subjected to trypsin digestion and LC-
MS analysis. In the mass range of 60–65 kDa, two can-
didate targets of JP104—carboxylesterase 6 (CE6) and
esterase 31 (Est31)—were identified. These enzymes
were confirmed as specific targets of JP104 by re-
combinant expression in COS7 cells (Figure 5A). Using
competitive ABPP [39], in which transfected COS7 cell
proteomes were first pretreated with varying concentra-
tions of JP104 (0.01–10 mM) and then incubated with FP-
Rh (100 nM), we estimated IC50 values of 0.05 and 2 mM
for CE6 and Est31, respectively (Figure 5B and Table
S1). CE6 was also inhibited by URB597 with similar po-
tency (IC50 = 0.2 mM, Figure 5B), while Est31 was not
labeled by this carbamate in vitro (Table S1). To test
Figure 5. Characterization of In Vivo Off-Target Sites of FAAH-
Directed Carbamates
(A) Labeling of recombinant CE6 and Est31 in transfected COS7 cell
proteomes by JP104 (1 mM).
(B) Inhibition of FP-Rh labeling of recombinant CE6 by JP104 and
URB597 (100 nM FP-Rh, 0.01–100 mM JP104 and URB597). From
these data sets, IC50 values of approximately 50 and 200 nM were
estimated for JP104 and URB597, respectively (see Table S1 for
complete data on CE6 inhibition). I, inhibitor.
(C) Inhibition of FAAH and CE6 by URB597 in vivo. Administration of
URB597 to mice (10 mg/kg, i.p., 1 hr) blocked JP104 labeling of
brain FAAH (left panel) and the 60–65 kDa liver target identified
as CE6 (right panel). JP104 labeling was conducted in vitro by using
membrane proteomes of tissues from URB597-treated mice and
was visualized by CC with RhN3. Equivalent inhibition of JP104
labeling of CE6 was observed in liver soluble proteomes from
URB597-treated mice (data not shown). Fluorescence images are
shown in grayscale.
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were treated with this inhibitor (10 mg/kg, i.p.) for 1 hr,
and the JP104-labeling profiles of excised tissues
were compared to those of vehicle-treated animals. In
addition to blocking JP104 labeling of FAAH in brain,
URB597 significantly reduced the labeling of the 60–65
kDa CE6/Est31 bands in liver (Figure 5C). Given that
only CE6 is sensitive to inhibition by URB597 in vitro,
we speculate that the labeling signals observed for the
60–65 kDa bands in vivo are predominantly derived
from this enzyme. Finally, dose-response studies with
URB597 revealed that this inhibitor and JP104 dis-
played similar efficacies for inhibiting FAAH (Figure
S3), indicating that URB597 also shows a moderate
(5- to 10-fold) range of selectivity for this enzyme over
CE6 in vivo.
Discussion
Nearly 30% of the enzymes targeted by drugs in clinical
use today are inhibited by a covalent irreversible mech-
anism [40]. This surprisingly large percentage suggests
that prejudices against the development of irreversible
inhibitors as therapeutic agents are overstated. The pri-
mary concern with covalent agents is that their inherent
reactivity will result in a lack of target selectivity in vivo,
although this presumption is rarely tested in a compre-
hensive way. Here, we describe a general strategy to
map the proteome-wide reactivity of covalent inhibitors
in vivo. This approach, which was used to evaluate the
selectivity of carbamate inhibitors of the endocannabi-
noid-degrading enzyme FAAH, exploits the bioorthogo-
nal CC reaction to modify inhibitor-labeled enzymes
with reporter tags for their direct visualization, enrich-
ment, and identification [35, 36]. Notably, the success
of this CC strategy hinged on a detailed understanding
of the mechanism of carbamate inhibition of FAAH,
such that an alkyne could be appended to the segment
of the inhibitor (the N-alkyl group) that remained bound
to the FAAH active site.
Using an alkyne-derivatized carbamate (JP104), we
identified multiple enzymes inactivated by FAAH-
directed carbamates in vivo, including both known
(Est31) and uncharacterized (CE6) proteins. It is perhaps
not surprising that these off-targets of JP104 are, like
FAAH, serine hydrolases, given that carbamates show
a preferred reactivity with enzymes from this class.
Nonetheless, it is important to emphasize that the ap-
proach described herein is not limited, like previously
described ABPP methods [39, 41], to profiling small-
molecule targets within a given enzyme class, but rather
can identify any protein susceptible to covalent in-
activation by chemical probes. Moreover, because CC
methods can be applied to study small-molecule-pro-
tein interactions in vivo, they take into account several
key factors, such as compound biodistribution and me-
tabolism, as well as the dynamic regulation of enzyme
localization and activity, that are not effectively ad-
dressed with in vitro methods.
By integrating information on the in vivo efficacy and
selectivity of JP104, a dose range was identified over
which FAAH could be inhibited without extensive label-
ing of other enzymes. The comparison of in vivo reactiv-
ity profiles at several doses of probe was critical forestablishing the extent of labeling of individual proteins
and normalizing for differences in relative enzyme abun-
dance. For example, at 1.0 mg/kg JP104, stronger abso-
lute signal intensities were observed for off-targets in
the liver and kidney than for FAAH in the brain (Figure
3B). However, administration of higher doses of JP104
(10 mg/kg) revealed that only a modest fraction of these
off-targets was labeled at lower doses, while FAAH la-
beling was nearly complete at 1 mg/kg probe (Figures
3B and 4). These results suggest that the liver and kid-
ney off-targets likely represent more abundant, but
less potently inhibited, targets of JP104 than FAAH,
a premise that is also supported by in vitro IC50 calcula-
tions (JP104 inhibited FAAH and CE6 with IC50 values of
approximately 2 and 50 nM, respectively). Thus, these
studies appear to have defined an acceptable pharma-
cological window for the administration of FAAH inhibi-
tors in vivo, at least for basic research purposes in mice.
The application of FAAH inhibitors in clinical settings
may require a greater selectivity index than is afforded
by current compounds. Future medicinal chemistry
efforts aimed at optimizing the specificity of FAAH-
directed carbamates should be assisted by the identifi-
cation of enzymes like CE6 that represent general ‘‘hot
spots’’ of reactivity for these compounds in vivo. In this
regard, it is worth noting that neither CE6 nor Est31
share any sequence similarity with FAAH, thus reinforc-
ing the notion that sequence-unrelated enzymes can
share significant active site homology [18, 39] and high-
lighting the importance of unbiased approaches for the
evaluation of inhibitor selectivity in vivo.
Some potential limitations of the CC approach should
also be noted. First, in situ proteome reactivity data sets
are currently analyzed by one-dimensional gel electro-
phoresis, which has limited resolving power and there-
fore may fail to identify certain lower-abundance
targets that comigrate with more highly expressed pro-
teins. For example, while the labeling of FAAH by JP104
could be visualized in brain, this enzyme was not de-
tectable in liver and kidney proteomes due to comigrat-
ing targets, even though these tissues are known to
express FAAH. Recent advances in gel-free (LC-MS-
based) approaches for chemical proteomics should ad-
dress this issue [42, 43]. A second concern relates to
how chemical derivatization might affect the proteome
reactivity profile of covalent drugs. Though the addition
of an alkyne group to the structures of most small mol-
ecules should be feasible with minimal steric perturba-
tion, this modification could still, in certain cases, alter
a compound’s binding and/or reactivity. This issue
can at least be partially addressed by in vivo competi-
tion studies, in which the parent inhibitor is used to
block the labeling of probe targets, as was carried out
with the URB597/JP104 small-molecule/probe pair
(Figure 5C). In such assays, ‘‘false positive’’ signals
(i.e., proteins that selectively react with the probe)
would be detected as targets whose labeling is not
competed by excess inhibitor. ‘‘False negative’’ signals
(i.e., proteins that selectively react with the parent inhib-
itor) might be revealed by constructing multiple probes
in which the alkyne is incorporated at different locations
on the parent inhibitor structure.
The in vivo profiling methods described herein should
be applicable to any compound that operates through
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itors are often viewed unfavorably as potential therapeu-
tic agents [34], they do possess some advantages over
reversible compounds. For example, as has been previ-
ously noted [44], irreversible inhibitors typically lead to
the complete and long-lasting inactivation of target pro-
teins, thus generating maximal pharmacological effects
from a single administration. In addition, because cova-
lent compounds can inactivate enzymes at concentra-
tions far below their respective binding constants, low
quantities of drug are required in vivo, and nonspecific
interactions that would otherwise occur at high com-
pound levels may be avoided. These observations, cou-
pled with the advent of general methods to directly
identify the proteins labeled by reactive small molecules
in vivo, suggest, perhaps somewhat counterintuitively,
that it may be easier to comprehensively assess and op-
timize the selectivity of irreversible inhibitors compared
to reversible agents. The success of such integrated
functional proteomic and medicinal chemistry endeav-
ors has the potential to reshape our views on the suit-
ability of covalent small molecules as pharmacological
agents for basic research and clinical applications.
Significance
Fatty acid amide hydrolase (FAAH) terminates the sig-
naling function of a large and diverse class of endog-
enous signaling lipids referred to as fatty acid amides.
Carbamate inhibitors of FAAH have been reported to
show analgesic and anxiolytic properties in rodents.
However, the mechanism by which carbamates inhibit
FAAH has remained obscure, thus complicating the
rational design of agents with improved potency and
selectivity. Here, we provide direct biochemical evi-
dence that carbamates covalently modify the active
site of FAAH and use this information to design a se-
ries of inhibitors that display enhanced potency. One
of these carbamates was converted into a ‘‘click chem-
istry’’ probe for in vivo analysis of FAAH activity and
inhibition. This activity-based probe was used to com-
prehensively assess the proteome reactivity of FAAH-
directed carbamate inhibitors in vivo, revealing that
these agents are selective for FAAH in the nervous
system but react with several other enzymes in periph-
eral tissues. In vivo dose-response curves identified
a modest window of selectivity (w5- to 10-fold) across
which carbamates could inhibit FAAH without exten-
sive labeling of off-target enzymes. The general exper-
imental strategy presented herein can be applied to
create in vivo functional probes for any enzyme sus-
ceptible to covalent inhibition. Considering that
nearly 30% of the enzymes targeted by drugs in cur-
rent clinical use are inhibited by an irreversible mech-
anism, we anticipate that click chemistry probes
should play a major role in the future development
of enzyme inhibitors for both basic research and clin-
ical applications.
Experimental Procedures
Synthesis of Inhibitors
See Supplemental Data.MS Analysis of Carbamate Labeling Site of FAAH
Inhibitor labeling reactions were conducted at room temperature
with 10 mM recombinant purified FAAH (w30 mg) prepared as de-
scribed previously [45] and 200 mM URB597 or URB532 in 125 mM
Tris$HCl (pH 9.0), 0.01% Triton X-100 in a total volume of 50 ml.
Any noncovalent interactions between probe and enzyme were dis-
rupted by gel filtration through a Biorad 10DG column, and the de-
sired fractions were concentrated to 50 ml by using an Amicon Ultra
centrifugal filter device, MWCO 10,000. Samples were then dena-
tured in 8 M urea and subjected to reduction, alkylation, and tryptic
digestion according to established procedures [46]. Samples (50 ml
after concentration under reduced pressure) were desalted by C18
ZipTip (Millipore) eluting in 4 ml (3:1 acetonitrile/water with 0.1% tri-
fluoroacetic acid) and were analyzed by MALDI-TOF Reflectron
mass spectrometry (Applied Biosystems Voyager STR) with 1:1 ma-
trix a-cyano-4-hydroxycinnamic acid:sample (1 ml total volume). For
tandem MS analysis, recombinant purified FAAH (w30 mg) in 125
mM Tris$HCl (pH 9) was reacted with URB597 as described above
and was then directly subjected to the tryptic digestion protocol.
The resulting peptide mixture (50 ml after concentration under re-
duced pressure) was analyzed by reverse-phase liquid chromatog-
raphy-electrospray ionization tandem MS (Finnigan LCQ Deca ion
trap MS; Thermo Finnigan). The gradient elution began with 100%
buffer A (95:5 vol/vol water/acetonitrile containing 0.1% formic
acid) for 10 min, followed by an increase to 15% buffer B (80:20
vol/vol acetonitrile/water containing 0.1% formic acid) in 5 min.
The gradient increased linearly to 50% buffer B in 75 min, followed
by an increase to 100% buffer B in 10 min, and ending with 100%
buffer B for 10 min. Tandem mass spectra were searched against
a database containing the rat FAAH sequence by using a modified
version of the SEQUEST algorithm. Search results were filtered
and grouped with DTASelect [47].
Preparation of Mouse Tissue Proteomes for CC Analysis
Mouse tissues were Dounce-homogenized in 10 mM sodium/potas-
sium phosphate buffer (pH 8.0) (PB), followed by a low-speed spin
(890 3 g) to remove debris. The supernatant was then subjected to
centrifugation at 100,0003 g for 45 min to provide the cytosolic frac-
tion in the supernatant and the membrane fraction as a pellet, which
was washed and resuspended in PB buffer by sonication. The total
protein concentration in each fraction was determined by a protein
assay kit (Bio-Rad). Samples were stored at 280ºC until use.
In Vitro Analysis of Inhibitor Potency
Inhibitor analysis was carried out in vitro by using two different as-
says. First, a radioactive substrate assay was employed by using
purified, recombinant FAAH as described previously [32, 45].
Briefly, FAAH activity was determined in the presence of varying
concentrations of inhibitors (0.01–100 mM, 503 DMSO stocks) by
following the conversion of [14C]oleamide to oleic acid by thin-layer
chromatography. Inhibitor potency was also examined by using
competitive ABPP as described previously [39]. Briefly, membrane
proteomes of mouse tissues were diluted to 1 mg/ml and preincu-
bated with varying concentrations of inhibitors (10 nM–100 mM,
503 DMSO stocks) for 10 min at room temperature prior to the ad-
dition of a rhodamine-tagged fluorophosphonate (FP-Rh; [38])
ABPP probe at a final concentration of 100 nM in a 50 ml total reac-
tion volume. Reactions were quenched after 10 min with one volume
23 SDS loading buffer (reducing with protease inhibitor), run on
SDS-PAGE, and visualized with a flatbed fluorescence scanner.
Dose-response curves obtained from both methods from three tri-
als at each inhibitor concentration were fit with Prism software
(GraphPad) to obtain IC50 values with 95% confidence intervals.
In Vitro CC Analysis of Proteins with JP104
Proteome samples (43 ml of 1 mg/ml protein in PB) were treated with
100 nM JP104 (unless otherwise indicated) (1 ml of a 5 mM DMSO
stock) for 1 hr at room temperature, followed by CC reaction with
25 mM rhodamine-azide (RhN3, 1 ml of a 1.25 mM DMSO stock) as
previously described [35, 36]. Samples were analyzed separately
by competitive ABPP with 1 mM FP-Rh instead of the CC reaction
with RhN3. Reactions were quenched with an equal volume (50 ml)
of 23 SDS loading buffer (reducing with protease inhibitor), run on
SDS-PAGE, and visualized by in-gel fluorescence scanning with a
Chemistry & Biology
1186Hitachi FMBio IIe flatbed laser-induced fluorescence scanner
(MiraiBio, Alameda, CA).
In Vivo Labeling in Mice
Mice (male C57BL/6 or FAAH2/2 [5]), weighed between 20 and 30 g
and were between the ages of 12 and 18 weeks. Mice were given in-
traperitoneal (i.p.) injections of JP104 (0, 0.25, 1, and 10 mg/kg) or
URB597 (0, 0.1, 0.2, 1, and 10 mg/kg) in vehicle (18:1:1 saline:emul-
phor:EtOH). The mock injections (0 mg/kg) consisted solely of vehi-
cle. After 1 hr, the mice were sacrificed by CO2 asphyxiation and
decapitation, and relevant tissues were flash frozen (with liquid
N2) immediately upon removal. Tissues were processed as de-
scribed above to isolate membrane and cytosolic proteomes. The
CC reaction and/or FP-Rh labeling were carried out as described
above, and reactions were analyzed by SDS-PAGE. The average
of three independent samples at each concentration was reported.
Protein Isolation and Identification from Mouse Liver
To identify off-target sites of reactivity in the liver, trifunctional
probes with biotin, Rh, and an azide [36] were used to affinity purify
in vivo-labeled enzymes for identification by mass spectrometry
techniques. The soluble liver proteome (2.5 ml, 3 mg/ml protein)
from a mouse treated with JP104 (10 mg/kg, i.p.) was subjected
to PD-10 size-exclusion chromatography to remove excess probe
and was then fractionated by Q-Sepharose chromatography (0–2
M NaCl gradient). Fractions containing desired material were com-
bined, and a 480 ml aliquot was subjected to CC reaction with the tri-
functional azide probe. The excess CC reagents were removed in
a series of washes as previously described [36]. Tagged proteins
were enriched by using avidin-agarose beads, and the affinity-
isolated proteins were separated by SDS-PAGE as previously de-
scribed [36]. Gel bands were identified by in-gel fluorescence
scanning, excised, and subject to in-gel trypsin digest [36]. The re-
sulting peptides were analyzed by mLC-MS/MS, and the results
were searched against public databases by using SEQUEST to
identify probe-labeled proteins as carboxylesterase 6 (CE6; GI#
20071857) and esterase 31 (Est31; GI# 2494382). These off-target
proteins were further verified by purchasing expressed sequence
tags (Open Biosystems), sequencing, and transient transfection
into COS7 cells as described previously [39]. Cytosolic fractions
from transfected cells were isolated by centrifugation and were an-
alyzed in vitro as described above to confirm labeling with JP104.
IC50 values were determined via competitive ABPP as described
previously [39].
Supplemental Data
Supplemental Data including synthesis of inhibitors and probes and
figures showing additional proteome labeling results and a compar-
ison of JP104 and URB597 dose-response profiles are available at
http://www.chembiol.com/cgi/content/full/12/11/1179/DC1/.
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